Skip to search formSkip to main contentSkip to account menu

PF-2341066

Known as: PF-02341066, C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066, PF 2341066 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

crizotinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the… 
2015
2015
Choroidal Metastases From EML4-ALK-Positive Non-Small-Cell Lung Adenocarcinoma.
Case Report A 31-year-old man presented with a 2-week history of intermittent flashes in both eyes. Visual acuity was 20/20 in… 
2012
2012
Effect of PF-02341066 and radiation on non-small cell lung cancer cells
Recently, a fusion protein of echinoderm microtubule associated protein like-4 (EML4) and anaplastic lymphoma kinase (ALK) has… 
Review
2012
Review
2012
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
Introduction: Most NSCLC patients are diagnosed in the advanced stage of the disease. Recently, chemotherapeutic agents have… 
2011
2011
Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.
e13065 Background: Crizotinib is a selective, ATP-competitive, small molecule inhibitor of the ALK and MET/HGF receptor tyrosine… 
2011
2011
Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor -
EML4-ALK is an oncogenic fusion kinase which was first identified in non-small cell lung cancer (NSCLC), and is regarded as an… 
2011
2011
Abstract 4563: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL The purpose of this study was to provide the first pre… 
2011
2011
Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification.
4130 Background: Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular marker for… 
2010
2010
Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)
Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified in anaplastic large cell lymphoma (ALCL… 
2010
2010
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) and TPM3-ALK (nonmuscular tropomyosin 3-anaplastic lymphoma kinase) are… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)